Jesse Geiger Sells 31,707 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) President Jesse Geiger sold 31,707 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medpace Trading Up 1.3%

MEDP stock traded up $6.12 during trading on Thursday, hitting $460.92. 285,609 shares of the stock traded hands, compared to its average volume of 345,623. The stock has a market cap of $13.08 billion, a price-to-earnings ratio of 30.13, a P/E/G ratio of 2.18 and a beta of 1.44. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The company has a 50 day simple moving average of $514.72 and a 200 day simple moving average of $538.54.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the prior year, the firm earned $3.67 earnings per share. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MEDP. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday, February 13th. Mizuho set a $582.00 target price on Medpace in a research note on Wednesday, February 11th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $486.67.

Institutional Investors Weigh In On Medpace

Hedge funds and other institutional investors have recently made changes to their positions in the company. Clarkston Capital Partners LLC acquired a new position in Medpace in the second quarter valued at about $40,569,000. Cibc World Market Inc. acquired a new position in shares of Medpace during the 3rd quarter worth about $5,033,000. Brighton Jones LLC grew its position in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after buying an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Medpace by 150.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after acquiring an additional 9,117 shares during the last quarter. Finally, Baillie Gifford & Co. increased its stake in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after acquiring an additional 62,503 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.